8-K: Solidion Technology Finalizes Employment Agreements with Key Executives

Solidion Technology, Inc. formalizes employment agreements with its Chief Science Officer and Chief Technology Officer, outlining compensation, benefits, and equity incentives.

Summary

• Solidion Technology, Inc. (STI) has entered into employment agreements with Dr. Bor Jang, Chief Science Officer, and Dr. Songhai Chai, Chief Technology Officer, effective February 10, 2025.
• Dr. Jang's agreement includes a starting annual base salary of $200,900 and a discretionary bonus target of 40% of his base salary, with at least 25% paid in cash.
• Dr. Jang will also receive a one-time transition bonus of $63,935.89 and initial grants of warrants to purchase 400,000 shares and 200,000 shares of unrestricted stock.
• Annually, Dr. Jang will receive 200,000 shares of restricted stock, vesting in three equal installments.
• Dr. Chai's agreement includes a starting annual base salary of $225,000 and a discretionary bonus target of 40% of his base salary, with at least 25% paid in cash.
• Dr. Chai will receive a one-time transition bonus of $99,041.10 and initial grants of warrants to purchase 200,000 shares and 100,000 shares of unrestricted stock.
• Annually, Dr. Chai will receive 100,000 shares of restricted stock, vesting in three equal installments.
• Both agreements have an initial term of two years, commencing on February 2, 2024, with annual renewal options.
• The agreements include provisions for severance benefits upon termination without cause or for good reason, including 12 months of base salary and health insurance continuation.
• Both executives are subject to confidentiality, non-solicitation, and non-competition clauses.

Sentiment

Score: 7

Explanation: The document is neutral to positive, outlining standard employment terms for key executives. The formalization of these agreements provides clarity and stability, which is generally viewed favorably.

Positives

• Formalizing employment agreements with key executives provides stability and clarity.
• The incentive structure, including base salary, bonuses, and equity, aligns executive interests with company performance.
• The agreements include standard protections for the company, such as confidentiality, non-solicitation, and non-competition clauses.
• The two-year initial term with renewal options allows for flexibility and performance evaluation.
• Equity grants provide a strong incentive for long-term value creation.

Negatives

• Dr. Jang's commitment of only 70% of his business time to Solidion Technology due to his role at G3 could be a potential concern.
• The discretionary nature of the bonus may lead to uncertainty or dissatisfaction if not managed transparently.
• The potential for severance payments could create a financial burden if executives are terminated without cause or resign for good reason.
• The non-renewal of the agreement requires a 60 day notice period which could be considered short.

Risks

• The reliance on key personnel like Dr. Jang and Dr. Chai poses a risk if they were to leave the company.
• The discretionary bonus structure could lead to disputes if performance metrics are not clearly defined and agreed upon.
• The non-competition clauses may not be fully enforceable in all jurisdictions, potentially limiting their effectiveness.
• The company's ability to attract and retain talent depends on maintaining competitive compensation and benefits packages.

Future Outlook

The employment agreements are subject to annual renewal, contingent on performance and mutual agreement. The company anticipates continued contributions from Dr. Jang and Dr. Chai in their respective roles.

Management Comments

• The Compensation Committee, made up entirely of independent directors, approved the company's entry into the Employment Agreements.
• Dr. Jang represents and warrants that he will devote approximately seventy percent (70%) of his business time and efforts to the performance of duties assigned to him under the Jang Employment Agreement.

Industry Context

In the competitive technology sector, attracting and retaining top talent is crucial. These employment agreements reflect Solidion Technology's commitment to securing experienced leadership in key scientific and technological roles.

Comparison to Industry Standards

• Executive compensation packages in the technology industry typically include a combination of base salary, performance-based bonuses, and equity incentives.
• Base salaries for CSO and CTO roles in similar-sized companies often range from $180,000 to $300,000, depending on experience and company performance.
• Equity grants are a common tool to align executive interests with long-term shareholder value, with vesting schedules typically spanning three to five years.
• Severance packages usually include 6 to 12 months of base salary and benefits continuation, contingent on signing a release agreement.

Related Party Transactions

• Dr. Jang's simultaneous employment by Global Graphene Group (G3), which beneficially owns approximately 51.4% of Solidion Technology's common stock, is a related party transaction that requires careful management to avoid conflicts of interest.

Stakeholder Impact

• Shareholders benefit from the formalized employment agreements, which provide stability and align executive interests with company performance.
• Employees gain clarity on the leadership structure and the company's commitment to attracting and retaining talent.
• Customers and suppliers can expect continued stability and expertise in the company's scientific and technological direction.

Next Steps

• The company will issue the equity awards to Dr. Jang and Dr. Chai, subject to Board approval and the availability of a Form S-8 registration statement.
• The Board will establish reasonable performance metrics for the executives' discretionary bonuses for the fiscal year ending December 31, 2025.
• The company will administer the employee benefit programs and perquisites as outlined in the employment agreements.

Key Dates